NeurogesX to market Qutenza for PHN on its own
This article was originally published in Scrip
Executive Summary
NeurogesX continues to prepare for US launch in the first half of 2010 for its high-dose capsaicin patch Qutenza (capsaicin 8%), for the management of neuropathic pain due to postherpetic neuralgia (PHN), but the company is not currently planning to seek a US marketing partner.